World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
64
Citations
15714
World Ranking
2923
National Ranking
109

Tuna Mutis publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Tuna Mutis sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 300 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Tuna Mutis D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Tuna Mutis sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 64 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Tuna Mutis is affiliated with the Vrije Universiteit Amsterdam in the Netherlands. Their research primarily spans the field of Medicine with a focus on Oncology, Immunology, Hematology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging. The subfields of study include:

  • Oncology
  • Immunology
  • Hematology
  • Molecular Biology
  • Radiology, Nuclear Medicine and Imaging

The principal topics of their work concentrate on areas related to immune and cancer research, specifically:

  • CAR-T cell therapy research
  • Multiple Myeloma Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • T-cell and B-cell Immunology

Tuna Mutis has contributed to a number of scientific publications across several well-established venues, including:

  • Blood
  • HemaSphere
  • Cancers
  • Blood Advances
  • Clinical Cancer Research

Their recent papers include:

  • Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma, 2021, Blood Advances
  • Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab, 2020, Leukemia
  • CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide, 2020, Haematologica
  • Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence, 2021, Science Translational Medicine
  • Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment, 2021, Blood Cancer Journal

Frequent collaborators in their work include:

  • Sonja Zweegman
  • Niels W.C.J. van de Donk
  • Christie P.M. Verkleij
  • Wassilis S.C. Bruins
  • Kristine A. Frerichs

Best Publications

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

    Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker

  • Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

    Jakub Krejcik;Jakub Krejcik;Tineke Casneuf;Inger S. Nijhof;Bie Verbist

  • Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.

    W. A. Erik Marijt;Mirjam H. M. Heemskerk;Freke M. Kloosterboer;Els Goulmy

  • Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

    M. B. Overdijk;S. Verploegen;M. Bogels;M. van Egmond

  • Feasibility of Immunotherapy of Relapsed Leukemia With Ex Vivo–Generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens

    Tuna Mutis;Rob Verdijk;Ellen Schrama;Bennie Esendam

  • Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) Induces Stable Maturation of Functionally Active Human Dendritic Cells

    Rob M. Verdijk;Tuna Mutis;Ben Esendam;Janine Kamp

  • Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization

    Jorg Van Loosdregt;Yvonne Vercoulen;Teun Guichelaar;Yoony Y J Gent

  • CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

    Inger S. Nijhof;Inger S. Nijhof;Tineke Casneuf;Jeroen van Velzen;Berris van Kessel

  • Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.

    T. Mutis;G. Gillespie;E. Schrama;J.H.F. Falkenburg

  • Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

    Niels W. C. J. van de Donk;Maarten L. Janmaat;Tuna Mutis;Jeroen J. Lammerts van Bueren

  • In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens

    Anne M. Dickinson;Xiao Nong Wang;Lisbet Sviland;Florry A. Vyth-Dreese

  • Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin

    Yvonne van de Wal;Yvonne M. C. Kooy;Peter A. van Veelen;Salvador A. Peña

  • Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

    Michael. S. van der Veer;Michel de Weers;Berris van Kessel;Joost M. Bakker

  • A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

    Esther Drent;Maria Themeli;Renée Poels;Regina de Jong-Korlaar

  • Pregnancy induces minor histocompatibility antigen–specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy

    Rob M Verdijk;Antoinette Kloosterman;Jos Pool;Maarten van de Keur

  • Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

    Esther Drent;Richard W. J. Groen;Willy A. Noort Noort;Maria Themeli

  • Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

    Evelien Kneppers;Bronno van der Holt;Marie-Jose Kersten;Sonja Zweegman

  • Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab

    Jakub Krejcik;Jakub Krejcik;Kris A. Frerichs;Inger S. Nijhof;Berris van Kessel

  • Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation

    Eric Spierings;Corine J. Vermeulen;Mario H. Vogt;Lucie E.E. Doerner

  • Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib

    Inger S. Nijhof;Inger S. Nijhof;Richard W.J. Groen;Richard W.J. Groen;Willy A. Noort;Willy A. Noort;Berris van Kessel;Berris van Kessel

  • The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein.

    R. A. Pierce;E. D. Field;T. Mutis;T. N. Golovina

Frequent Co-Authors

Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Henk M. Lokhorst
Henk M. Lokhorst VU University Medical Center
Els Goulmy
Els Goulmy Leiden University Medical Center
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Gert Storm
Gert Storm Utrecht University
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
Anneke Brand
Anneke Brand Leiden University Medical Center
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center
Margaret A. Lindorfer
Margaret A. Lindorfer University of Virginia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare careers can open various opportunities. Many students pursue advanced nursing paths, such as becoming a Doctor of Nursing Practice (DNP). Understanding the doctor of nursing practice salary by state can help prospective students gauge the financial benefits alongside rigorous training.

If you're a Family Nurse Practitioner looking to specialize, obtaining an acute care NP certification is a valuable step. This certification allows nurses to focus on patients with severe, complex conditions, often aligned with immunological disorders.

Online education offers flexibility for those pursuing nursing careers related to immunology. Accelerated programs, such as the accelerated RN to NP programs, enable registered nurses to advance quickly in their careers, transitioning to nurse practitioners within a shorter timeframe.

For individuals new to the field, online RN programs for non nurses provide accessible entry points into nursing. These programs build foundational skills necessary to later specialize in areas like immunology or advanced practice nursing.

Best Scientists Citing Tuna Mutis

Trending Scientists

Recently Published Articles